Goto Biopharm released its first-quarter performance, with a net profit attributable to the parent company of 1.0821 million yuan, a decrease of 69.50%

According to the Zhitong Finance APP, Goto Biopharm (300966.SZ) released its first-quarter report for 2025, with operating revenue of 139 million yuan, a year-on-year increase of 13.90%. The net profit attributable to shareholders of the listed company was 1.0821 million yuan, a year-on-year decrease of 69.50%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.3366 million yuan, a year-on-year decrease of 61.42%. The basic earnings per share were 0.01 yuan